Navigation Links
CytImmune Presents Positive CYT-6019 Data During the American,Society of Clinical Oncology Annual Meeting in Chicago

Chicago, IL -- CytImmune, a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies today presented a poster abstract at the 43rd American Society of Clinical Oncology (ASCO) Annual meeting. The poster, entitled "Preliminary Results of a Phase 1 Clinical Trial of CYT-6901," announced the preliminary data of a National Cancer Institute conducted and CytImmune Sciences sponsored Phase 1 trial of CYT-6091 (Aurimune), CytImmune's lead drug compound. The Phase 1 clinical trial was designed to investigate whether: (1) Aurimune will perform identically in humans as it did in preclinical studies and companion animals and (2) the fever side effect observed in preclinical studies can be easily managed and separated from hypotension - the dose limiting side effect of the active pharmaceutical ingredient.

"This is a tremendous opportunity for CytImmune," said Dr. Lawrence Tamarkin. "Presenting preliminary Phase 1 trial results to the leading body of international oncology experts helps pave the way for nanomedicines as the next generation of targeted cancer therapies and their use in improving the biodelivery of potent, but highly toxic therapeutics. We believe CYT-6091 has the potential to become a new, versatile therapeutic which may be used to treat a broad spectrum of solid tumors."

CYT-6091 (Aurimune), CytImmune's lead drug compound, is recombinant human tumor necrosis factor alpha (TNF) bound to the surface of 27 nanometer PEGylated colloidal gold nanoparticles. While TNF's tumor killing properties are well documented, its clinical use has been severely limited due to unacceptable toxicities.

To harness the potential of this anti-cancer agent, CytImmune's approach simultaneously binds PEG-Thiol and TNF to the surface of colloidal gold nanoparticles, whose design is to: (1) make them invisible to immune detection, thereby av
'"/>




Page: 1 2 3

Related medicine technology :

1. CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to be Presented on June 3, 2007
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Indiana blocked the sale of ...
Breaking Medicine Technology:SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... FAIRFIELD, N.J., Jan. 28, 2011 The Healthcare ... of the Year" is Freda Lewis-Hall, MD, chief medical ... Dr. Lewis-Hall has held leadership roles in direct ... (Photo: http://photos.prnewswire.com/prnh/20110128/DC38263 ) ...
... 2011 TechniScan (OTC Bulletin Board: TSNI ... and commercialization of an automated 3D breast ultrasound imaging ... will present at RetailInvestorConferences.com. DATE: , February 3rd, ... This will be a live, interactive online event where ...
Cached Medicine Technology:Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 2Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 3Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 4TechniScan to Present Live, Online at RetailInvestorConferences.com on February 3rd 2
(Date:8/21/2014)... the environmental source of fungal infections that have been ... literally grows on trees. , The discovery is based ... spent the summer gathering soil and tree samples from ... the fungus named Cryptococcus gattii (CRIP-to-cock-us ... number of species including C. gattii , causes ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Black mothers ... babies, and here,s one possible reason why: Hospitals in ... nursing than those in areas with more white residents, ... support breast-feeding are much less common in medical centers ... from the U.S. Centers for Disease Control and Prevention ...
(Date:8/21/2014)... Among seniors, dimming vision may be tied to poorer ... 2,500 people, aged 65 to 84, who were assessed when ... eight years later. Vision loss over time was associated ... the study period, the researchers reported. Although the study ... of Purdue University in West Lafayette, Ind., offered up some ...
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... against C.R. Bard, Inc. continue to move forward ... District Court, Southern District of West Virginia, Bernstein ... issued on August 14th, the Court has established ... that requires special handling, division, storage and preservation. ...
(Date:8/21/2014)... to focus on her body in terms of how ... as a complete human being with thoughts and feelings. ... the media, how does it affect individual romantic relationships? ... , a SAGE journal, finds that more objectification of ... of sexual pressure and coercion., Researchers Laura R. Ramsey ...
Breaking Medicine News(10 mins):Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Objectification in romantic relationships related to sexual pressure and coercion 2
... in conjunction with their sponsor, Arnold Palmer Hospital, are hosting Grossology, ... , ... Orlando, FL (PRWEB) January 29, 2009 -- ... hosting Grossology : The (Impolite) Science of the Human Body, ...
... the National Association of Medicaid Fraud Control Units ... has joined the Whistleblower Action Network through his ... Carson City, Nevada. The Whistleblower Action Network ... citizens, known as "relators," who witness fraud against ...
... unique support program with the goal to help healthcare professionals optimize ... ... NJ (PRWEB) January 29, 2009 -- Though rare, gastrointestinal stromal tumors ... tract, with an estimated 3,300 to 6,000 new cases reported each ...
... - A New Year of Growth in 2008, ... - Higher Earnings Expected , ... revenue of EUR3,074.5 million for the year ended,December 31, 2008, representing ... growth for the year was a strong 9.7%. , ...
... new 692,000 research initiative launches today with the aim ... to bring vulnerable homeless people in from the margins ... a greater understanding of homeless people who have to ... drug or alcohol dependencies, severe mental health problems and ...
... School of Medicine (BUSM) and Boston Medical Center (BMC), in ... more than three months premature, are at three times the ... in toddlers (M-CHAT). Children who screen positive on M-CHAT ... findings appear in the January issue of Journal of ...
Cached Medicine News:Health News:Grossology Exhibit Captivates Kids at The Orlando Science Center 2Health News:Grossology Exhibit Captivates Kids at The Orlando Science Center 3Health News:Nationally Recognized Medicaid Fraud Prosecutor Tim Terry Joins Successful Whistleblower Law Practice, Specializing in "Qui Tam" Citizen Suits Under False Claims Acts 2Health News:Nationally Recognized Medicaid Fraud Prosecutor Tim Terry Joins Successful Whistleblower Law Practice, Specializing in "Qui Tam" Citizen Suits Under False Claims Acts 3Health News:Nationally Recognized Medicaid Fraud Prosecutor Tim Terry Joins Successful Whistleblower Law Practice, Specializing in "Qui Tam" Citizen Suits Under False Claims Acts 4Health News:Novartis Oncology Launches GIST Alliance™ for Healthcare Professionals Treating Gastrointestinal Stromal Tumors 2Health News:Novartis Oncology Launches GIST Alliance™ for Healthcare Professionals Treating Gastrointestinal Stromal Tumors 3Health News:Essilor : 2008 Revenue 2Health News:Essilor : 2008 Revenue 3Health News:Essilor : 2008 Revenue 4Health News:Essilor : 2008 Revenue 5Health News:Essilor : 2008 Revenue 6Health News:Is it possible to eradicate homelessness? 2Health News:Study finds preemies more likely to score positive 2
5L...
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... Family includes fixed-volume, adjustable-volume, and multichannel ... Eppendorf Research pro Pipette. Designed with ... high-performance pipettes have earned a worldwide ... use with original Eppendorf pipette tips, ...
10L...
Medicine Products: